Ramelteon is a selective MT 1/MT 2-receptor agonist indicated for insomnia treatment.
Because it has no depressant effects on the nervous system, it is not expected to affect the …

Ramelteon, a selective MT 1/MT 2 melatonin receptor agonist, was evaluated in subjects
with mild to moderate chronic obstructive pulmonary disease (COPD) to determine whether …

Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …

BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …

Study Objectives: To evaluate the effectiveness of ramelteon, a melatonin receptor agonist,
for the treatment of insomnia in older adults starting auto-titrating positive airway pressure …

Background Individuals with moderate to severe chronic obstructive pulmonary disease
(COPD) have poor sleep quality. This study evaluated the effects of ramelteon, an MT 1/MT 2 …

Ramelteon (Rozerem™) is the first melatonin receptor agonist to be approved for the
treatment of insomnia; it is not classified as a controlled substance. In patients with chronic …

Abstract Study Objectives: Long-duration (≥ 6 months) polysomnographic studies of
insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon …

Objective: To assess the efficacy and safety of ramelteon, a selective melatonin MT1/MT2-
receptor agonist, for insomnia treatment in older adults. Methods: In a randomized, 9‑week …

OBJECTIVE: To assess patient-reported efficacy and safety of ramelteon in Japanese
patients with chronic insomnia. METHODS: Randomized, double-blind, placebo-controlled …